SETTING: The tuberculin skin test (TST) is widely used as a diagnostic or screening test for Mycobacterium tuberculosis infection and disease. A peri-urban shantytown in the desert hills of south Lima, Peru, highly endemic for tuberculosis, and where bacille Calmette-Guérin (BCG) vaccine had been given in multiple doses until 1995. OBJECTIVE: To analyze the effect of multiple BCG vaccines on TST in a community-based setting. DESIGN: Point-prevalence survey of TST reactions of 572 people aged 6-26 years from 255 households. TST reactions were compared to the observed number of BCG scars and other potential risk factors (age, living with a TST-positive person, and contact with active tuberculosis). RESULT: People with two or more scars had significantly larger reactions, even after adjusting for potential risk factors. The adjusted population attributable fraction of being TST-positive and having two or more BCG scars was 26%. CONCLUSION: There is no demonstrated benefit of repeat BCG vaccination. We therefore recommend that physicians take into consideration the number of BCG scars when interpreting the TST and that programs give no more than one BCG vaccination.
SETTING: The tuberculin skin test (TST) is widely used as a diagnostic or screening test for Mycobacterium tuberculosis infection and disease. A peri-urban shantytown in the desert hills of south Lima, Peru, highly endemic for tuberculosis, and where bacille Calmette-Guérin (BCG) vaccine had been given in multiple doses until 1995. OBJECTIVE: To analyze the effect of multiple BCG vaccines on TST in a community-based setting. DESIGN: Point-prevalence survey of TST reactions of 572 people aged 6-26 years from 255 households. TST reactions were compared to the observed number of BCG scars and other potential risk factors (age, living with a TST-positive person, and contact with active tuberculosis). RESULT: People with two or more scars had significantly larger reactions, even after adjusting for potential risk factors. The adjusted population attributable fraction of being TST-positive and having two or more BCG scars was 26%. CONCLUSION: There is no demonstrated benefit of repeat BCG vaccination. We therefore recommend that physicians take into consideration the number of BCG scars when interpreting the TST and that programs give no more than one BCG vaccination.
Authors: C W Hoge; L Fisher; H D Donnell; D R Dodson; G V Tomlinson; R F Breiman; A B Bloch; R C Good Journal: Am J Epidemiol Date: 1994-03-01 Impact factor: 4.897
Authors: Leonardo Martinez; Alyssa Arman; Nathan Haveman; Ashley Lundgren; Lilia Cabrera; Carlton A Evans; Tom F Pelly; Mayuko Saito; David Callacondo; Richard Oberhelman; Gisela Collazo; Andrés M Carnero; Robert H Gilman Journal: Am J Trop Med Hyg Date: 2013-07-22 Impact factor: 2.345
Authors: T F Pelly; C F Santillan; R H Gilman; L Z Cabrera; E Garcia; C Vidal; M J Zimic; D A J Moore; C A Evans Journal: Int J Tuberc Lung Dis Date: 2005-09 Impact factor: 2.373
Authors: Juan A Gálvez-Buccollini; Suzanne DeLea; Phabiola M Herrera; Robert H Gilman; Valerie Paz-Soldan Journal: BMC Public Health Date: 2009-01-19 Impact factor: 3.295
Authors: Maitreyi Murthy; Sumithra Selvam; Nelson Jesuraj; Sean Bennett; Mark Doherty; Harleen M S Grewal; Mario Vaz Journal: PLoS One Date: 2013-09-06 Impact factor: 3.240
Authors: Sumona Datta; Jonathan M Sherman; Marco A Tovar; Marjory A Bravard; Teresa Valencia; Rosario Montoya; Willi Quino; Nikki D'Arcy; Eric S Ramos; Robert H Gilman; Carlton A Evans Journal: J Infect Dis Date: 2017-09-01 Impact factor: 5.226